Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker ...

EST Merck KGaA (MKGAY) in talks to buy SpringWorks Therapeutics (SWTX), Reuters reportsMaximize Your Portfolio with Data Driven ...

Springworks, which listed its shares in New York in 2019, is a commercial-stage biotech firm that develops drugs to treat various forms of cancer and other rare diseases such as uterine cancer and ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared 12% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions to acquire the cancer and rare disease drugmaker.

Before that, she spent the better part of two decades at EMD Serono, Merck KGaA’s U.S. pharma subsidiary. Her 18 years there spanned a range of roles across its commercial team, including stints ...

Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Why Merck (MRK) Stock Is Falling Today What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings.

Merck’s Q4 sales rose 7% YoY to $15.62B, slightly beating the $15.49B consensus. Adjusted EPS jumped to $1.72, topping estimates of $1.62. Keytruda sales grew 19% YoY to $7.84B, while Gardasil ...